HOME > COMMENTARY
COMMENTARY
-
Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics
July 26, 2017
-
Did Voice of the Industry Reach Honebuto Policymakers?
June 21, 2017
-
As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
June 14, 2017
-
MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
May 11, 2017
-
Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
April 19, 2017
-
“Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
April 12, 2017
-
Is the Government’s 70% Interim Generic Share Target Achievable?
March 13, 2017
-
Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
-
Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
February 6, 2017
-
Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
-
Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
December 14, 2016
-
Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
November 15, 2016
-
Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
October 25, 2016
-
Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
-
Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
-
Can Mid-sized Makers Break Away from Long-Listed Product Model?
August 19, 2016
-
MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
-
7 Drugs Picked for Cost-Effective Assessments, but Now How Will They Be Re-Priced Exactly?
May 27, 2016
-
Data Corroborate Harshness of Z2 Rule, Only Handful to Escape 2nd Consecutive Application
March 31, 2016
-
Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
March 11, 2016
ページ
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…